Keyphrases
Advanced Basal Cell Carcinoma
73%
Cemiplimab
39%
Sonidegib
38%
Hedgehog Inhibitor
36%
Advanced Cutaneous Squamous Cell Carcinoma
34%
Cutaneous Squamous Cell Carcinoma (cSCC)
33%
Basal Cell Carcinoma
32%
Vismodegib
29%
Objective Response Rate
23%
Metastatic Basal Cell Carcinoma
23%
Locally Advanced
22%
Long-term Efficacy
16%
Long-term Safety
12%
Mohs Micrographic Surgery
12%
Duration of Response
12%
Non-melanoma Skin Cancer
10%
Blinded Independent Central Review
10%
Metastatic Cutaneous Squamous Cell Carcinoma
10%
Locally Advanced Cutaneous Squamous Cell Carcinoma
9%
Phase II Study
9%
Advanced or Metastatic
9%
Head-and-neck
8%
Squamous Cell Carcinoma of Head
8%
Squamous Cell Carcinoma (SqCC)
8%
Complete Response
8%
Antitumor Activity
8%
Treatment Options
7%
Systemic Therapy
7%
Safety Profile
6%
Partial Response
6%
Head and Neck Cutaneous Squamous Cell Carcinoma
6%
Acceptable Safety
6%
Confidence Interval
6%
Adverse Events
6%
PD-1 Inhibitor
6%
Inhibitor Therapy
5%
Metastatic Cancer
5%
Treatment-related Adverse Events
5%
Surgical Excision
5%
Hedgehog Signaling Pathway
5%
Response Rate
5%
LDE225
5%
Dysgeusia
5%
Muscle Spasm
5%
Medicine and Dentistry
Skin Carcinoma
64%
Basal-Cell Carcinoma
62%
Diseases
27%
Sonidegib
26%
Neoplasm
24%
Non Melanoma Skin Cancer
22%
Hedgehog Signaling
19%
Malignant Neoplasm
18%
Cemiplimab
17%
Neck
16%
Metastatic Carcinoma
13%
Mohs Surgery
12%
Vismodegib
12%
Melanoma
11%
Immunotherapy
10%
Systemic Therapy
9%
Arm
9%
Cancer
9%
Squamous Cell Carcinoma
8%
Photograph
7%
Skin Cancer
7%
Disease Specific Survival
6%
Dermatosis
6%
Adverse Effect
5%
Oncology
5%
Actinic Keratosis
5%
Radiation Therapy
5%
Biopsy Technique
5%
Dermatology
5%
Diagnosis
5%
Clinical Trial
5%
Pharmacology, Toxicology and Pharmaceutical Science
Basal Cell Carcinoma
100%
Skin Carcinoma
53%
Hedgehog
46%
Cemiplimab
46%
Sonidegib
42%
Vismodegib
36%
Neoplasm
23%
Diseases
22%
Malignant Neoplasm
16%
Immunotherapy
13%
Adverse Event
12%
Non Melanoma Skin Cancer
9%
Pharmacokinetic
8%
Overall Survival
7%
Antitumor Activity
6%
Clinical Trial
6%
Head and Neck Squamous Cell Carcinoma
5%
Melanoma
5%
Systemic Treatment
5%